Advertisement

Topics

Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.

07:00 EST 1st January 2017 | BioPortfolio

Summary of "Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial."

Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson's disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of Parkinson's disease
ISSN: 1877-718X
Pages: 685-693

Links

DeepDyve research library

PubMed Articles [35122 Associated PubMed Articles listed on BioPortfolio]

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

Given the recognition that disease-modifying therapies should focus on earlier Parkinson's disease stages, trial enrollment based purely on clinical criteria poses significant challenges. The goal her...

Challenges to Informed Consent in First-In-Human Trials Involving Novel Treatments: A Case Study of Parkinson's Disease.

Obtaining informed consent in clinical trials can be challenging both for researchers and for patients, albeit in different ways. The challenge concerns not only how to provide the needed information,...

Constipation is not associated with DAT dopaminergic pathology in early de novo patients with Parkinson's disease.

Constipation is a common non-motor symptom of Parkinson's disease. Deposition of α-synuclein inclusions that spread from the gut to the substantia nigra through the vagus nerve has been recently spec...

Cognitive and Neuropsychiatric Features of Early Parkinson's Disease.

The clinical definition of Parkinson's disease (PD) is based on cardinal motor features including bradykinesia as well as an additional symptom of tremor, postural instability, or rigidity. Evidence f...

Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.

Substantial progress has been made in the discovery of blood biomarkers for Parkinson's disease (PD), a progressive neurodegenerative disease that affects more than 4 million worldwide. Olfactory dysf...

Clinical Trials [8497 Associated Clinical Trials listed on BioPortfolio]

A Study of KW-6356 in Subjects With Early Parkinson's Disease

The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score bet...

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

This is a clinical trial to be conducted at multiple Parkinson Study Group (PSG) sites in the USA. Patients with early Parkinson disease will be randomly allocated to one of 4 arms in the ...

Farming and Movement Evaluation Study (FAME)

The long term goal of this research is to elucidate the cause(s) of Parkinson's disease, with a focus on environmental determinants. We propose to investigate the relationship between Par...

Study for the Early Diagnosis of Parkinson's Disease

The main objective of the study is to design and validate the blood based PDx gene expression assay for the early diagnosis of Parkinson's disease patients. Differential diagnosis include...

SudoScan as a Biomarker of Parkinson's Disease

Currently, there is no clear diagnostic test that can be used to confirm the diagnosis of Parkinson's disease, or a biomarker that can track its progression. Patients with Parkinson's have...

Medical and Biotech [MESH] Definitions

Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754)

Proteins associated with sporadic or familial cases of PARKINSON DISEASE.

Earlier than planned termination of clinical trials.

A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Article